What are the IDSA recommendations for treatment of fluoroquinolone-resistant acute pyelonephritis (kidney infection)?

Updated: Jul 01, 2021
  • Author: Tibor Fulop, MD, PhD, FACP, FASN; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print
Answer

In communities where the prevalence of resistance in uropathogens to fluoroquinolones is not known to be greater than 10%, the IDSA guidelines advise that patients who do not require hospitalization be treated with oral ciprofloxacin, 500 mg twice daily for 7 days, with or without an initial 400-mg dose of intravenous ciprofloxacin. If the uropathogen’s fluoroquinolone resistance is greater than 10%, an initial intravenous dose of a long-acting parenteral antimicrobial (eg, ceftriaxone, 1 g) is recommended. [3]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!